Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | GALR3 | O60755 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10510831 | 1.00 | TSHR (0.41) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL10508099 | 1.00 | TSHR (0.41) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL570203 | 1.00 | TSHR (0.41) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL10506976 | 1.00 | TSHR (0.41) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL2117269 | 1.00 | TSHR (0.41) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL10735194 | 1.00 | TSHR (0.41) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL10508209 | 1.00 | TSHR (0.41) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL3060848 | 1.00 | TSHR (0.41) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL10508715 | 1.00 | TSHR (0.41) | TSHRTDP1CHRM2CHRM4CHRM1 | |
| SCHEMBL10506819 | 0.94 | TSHR (0.42) | TSHRTDP1CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240117400-A1 | T CELLS WITH REDUCED SURFACE FUCOSYLATION AND METHODS OF MAKING AND USING THE SAME | SEAGEN INC (US) | 2024-04-11 | — | — | US | disclosed |
| US-11891644-B2 | T cells with reduced surface fucosylation and methods of making and using the same | SEAGEN INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-20230055475-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | SEAGEN INC (US) | 2023-02-23 | — | — | US | disclosed |
| US-11319526-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | SEAGEN INC. (US) | 2022-05-03 | — | — | US | disclosed |
| CN-113438951-A | Controlled fucosylation of antibodies | 西根股份有限公司 | 2021-09-24 | — | — | CN | disclosed |
| US-11033561-B2 | Methods of inhibition of protein fucosylation in vivo using fucose analogs | SEAGEN INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200149082-A1 | T CELLS WITH REDUCED SURFACE FUCOSYLATION AND METHODS OF MAKING AND USING THE SAME | SEAGEN INC. | 2020-05-14 | — | — | US | disclosed |
| EP-3634427-A1 | T CELLS WITH REDUCED SURFACE FUCOSYLATION AND METHODS OF MAKING AND USING THE SAME | Seattle Genetics, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20200061091-A1 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | SEATTLE GENETICS, INC. (US) | 2020-02-27 | — | — | US | disclosed |
| CN-110740734-A | T cells with reduced surface fucosylation and methods of making and using the same | 西雅图基因公司 | 2020-01-31 | — | — | CN | disclosed |
| US-7335500-B2 | Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of GDP-fucose | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-02-26 | — | — | US | disclosed |
| US-20020068331-A1 | Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of GDP-fucose | WONG CHI-HUEY (US) | 2002-06-06 | — | — | US | disclosed |
| US-6319695-B1 | FORMING A GLYCOSIDE BOND BY ETHERIFICATION AND CIRCULATION | THE SCRIPPS RESEARCH INSITUTE | 2001-11-20 | — | — | US | disclosed |
| EP-0642526-B1 | PRODUCTION OF FUCOSYLATED CARBOHYDRATES BY ENZYMATIC FUCOSYLATION SYNTHESIS OF SUGAR NUCLEOTIDES; AND IN SITU REGENERATION OF GDP-FUCOSE | SCRIPPS RESEARCH INST (US) | 1998-12-23 | — | — | EP | disclosed |
| EP-0642526-A4 | PRODUCTION OF FUCOSYLATED CARBOHYDRATES BY ENZYMATIC FUCOSYLATION SYNTHESIS OF SUGAR NUCLEOTIDES; AND IN SITU REGENERATION OF GDP-FUCOSE. | SCRIPPS RESEARCH INST (US) | 1996-04-10 | — | — | EP | disclosed |
| EP-0642526-A1 | PRODUCTION OF FUCOSYLATED CARBOHYDRATES BY ENZYMATIC FUCOSYLATION SYNTHESIS OF SUGAR NUCLEOTIDES; AND IN SITU REGENERATION OF GDP-FUCOSE | THE SCRIPPS RESEARCH INSTITUTE (US) | 1995-03-15 | — | — | EP | disclosed |
| WO-1993008205-A1 | PRODUCTION OF FUCOSYLATED CARBOHYDRATES BY ENZYMATIC FUCOSYLATION SYNTHESIS OF SUGAR NUCLEOTIDES; AND IN SITU REGENERATION OF GDP-FUCOSE | THE SCRIPPS RESEARCH INSTITUTE (US) | 1993-04-29 | — | — | WO | disclosed |
| EP-0173462-B1 | ELLIPTICINE DERIVATIVE AND PRODUCTION PROCESS THEREOF | SUNTORY LIMITED (JP) | 1989-10-25 | — | — | EP | disclosed |
| US-4698423-A | ANTITUMOR AGENTS | SUNTORY LIMITED (JP) | 1987-10-06 | — | — | US | disclosed |
| EP-0173462-A2 | Ellipticine derivative and production process thereof | SUNTORY LIMITED (JP) | 1986-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055475-A1 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION | FUT5, FUCA2, FCGR3B | TSHR 1665/4885TDP1 4741/4885CHRM2 4627/4885 |
| US-20200061091-A1 | METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS | FUCA1, FUCA2, FUT4 | TSHR 3062/4885TDP1 4730/4885CHRM2 4795/4885 |
| US-11033561-B2 | Methods of inhibition of protein fucosylation in vivo using fucose analogs | FUCA1, FUCA2, FUT4 | TSHR 3062/4885TDP1 4730/4885CHRM2 4795/4885 |
| US-20240117400-A1 | T CELLS WITH REDUCED SURFACE FUCOSYLATION AND METHODS OF MAKING AND USING THE SAME | CD4, FUCA2, CD2 | TSHR 1413/4885TDP1 3742/4885CHRM2 4763/4885 |
| US-11319526-B2 | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation | FUT5, FUCA2, FCGR3B | TSHR 1665/4885TDP1 4741/4885CHRM2 4627/4885 |
| US-20200149082-A1 | T CELLS WITH REDUCED SURFACE FUCOSYLATION AND METHODS OF MAKING AND USING THE SAME | CD4, FUCA2, CD2 | TSHR 1413/4885TDP1 3742/4885CHRM2 4763/4885 |
| US-11891644-B2 | T cells with reduced surface fucosylation and methods of making and using the same | CD4, FUCA2, CD2 | TSHR 1413/4885TDP1 3742/4885CHRM2 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.